Antimicrobial Agents and Chemotherapy · 1996 · 13 citations · 9 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMedical MicrobiologyMycologyAntifungal AgentsAntifungal PharmacologyAntifungal ResistanceAntifungal TherapyFungal InfectionsFungal PathogenesisCandidiasis Drug ResistanceFungal Drug DiscoveryFungal Drug ResistanceNew Antifungal AgentsNovel Antifungal Drug DevelopmentResistance In Clinical Isolates
We compared the in vitro activity of BMS-181184, the first compound of a new class of antifungal agents, the pradimicins, with those of fluconazole and amphotericin B against 64 clinical isolates of Candida species. MICs were determined by a microdilution method with high resolution medium for BMS-181184 and fluconazole and antibiotic medium no. 3 with 2% glucose for amphotericin B. MICs of BMS-181184 for all yeasts were in the range of 0.78 to 12.5 micrograms/ml. BMS-181184 was active against isolates resistant to other antifungal agents, consistent with a novel mode of action. Minimum fungicidal concentrations for 16 isolates showed that BMS-181184 was fungicidal. Clinical studies are now required to confirm its activity.
9
Elizabeth M. Johnson, David W. Warnock, Jane Luker et al. · Journal of Antimicrobial Chemotherapy · 1995 · 256 citations
Fluconazole resistance in Candida glabrata
Christopher A. Hitchcock, G. W. Pye, Peter F. Troke et al. · Antimicrobial Agents and Chemotherapy · 1993 · 243 citations · Full text
Medicine, Microbiology, Pharmacology +17